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Abstract. Experiments utilising either tumour cells or over-expression of oncogenes 
like Ras and its potential downstream mediators have yielded a wealth of 
information over the last decade. Qualitative and quantitative analysis of AP-1 
transcription factor has been extensively analysed in response to various oncogenic 
signals. One basic criticism is that the continued presence of an activated component 
of cellular signaling renders the study of early Sai-mediated signaling impossible. 
Inducible systems for oncogene expression offer a valuable alternative for detailed 
analysis of signal transduction pathways. Here, we report the comparative analysis 
of components of oncogenic pathways between tumour cells and cells that carry 
inducible oncogenes. 
1. AP-1 composition 
Transcription factor AP-1 (activator protein 1) plays an important role in cell proliferation, 
differentiation, apoptosis and malignant transformation. Homo and heterodimeric complexes of 
Jun, Fos and ATF family members form the DNA binding complex thus regulating 
transcription.. Homodimers of c-Jun protein and c-Jun/c-Fos heterodimers bind to the AP-1 
consensus sequence TGAC/GTCA [1]. C-Jun/ATF-2 heterodimers and ATF-2 homodimers 
preferably bind to the ATF/CREB consensus sequence TG/TACGTCA [2]. Signal transduction 
pathways initiated at the cell surface in response to cytokines, growth factors, tumour promoters 
and overexpression of certain oncogenes [3] finally regulate members of all three families. The 
jun family comprises three members (c-jun, junB, and junD) [4-6] and the fos family four 
different genes (c-fos, fos B, fra-l, fra-2) [7-9]. Activating transcription factor 2 (ATF-2) is a 
member of the ATF/CREB bZip family of transcription factors [10]. ATF-2 plays important 
roles in the early events of signaling pathways, since phosphorylation of this factor by the c-jun-
N-terminus-associated kinases increases its trans-activating properties and permits the early 
activation of the c-jun promoter [11]. AP-1 activity is regulated at the level of transcription of 
jun and fos genes, by protein-protein interactions and post-translational modifications of Jun 
and Fos proteins [12-14]. 
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2. Ras signalling and A P I 
The p21Ras proteins are frequently mutated in human tumours [15] and provide a link between 
receptors at the cell membrane with the cytoplasmic cascade of protein kinases followed by 
downstream nuclear events, including induction of transcription and DNA synthesis [16]. 
Mutant Ras proteins have been shown to regulate AP-1 activity at transcriptional and post-
translational levels [17-19]. Among the y'««'family genes that encode for transcription factors, 
only c-jun displays full transforming potential in cooperation with activated Η-ras in primary 
rat embryo fibroblasts [20]. Phosphorylation of N-terminal c-Jun protein residues Ser-63 and 
Ser-73 by JNK kinases is necessary for transactivation and oncogene cooperation using in vitro 
transformation assays. AP-1 transcriptional response and the ability to be transformed by 
activated Ras proteins are markedly impaired in cells carrying a homozygous null mutation of 
the c-jun gene [21]. JunB and JunD can also cooperate with Ras to induce foci, but with less 
efficiency compared to c-Jun [22-23]. JunD protein has been reported to efficiently suppress 
transformation by an activated ras gene [24]. Investigation of Fos protein levels has shown that 
Fra-2 protein plays a crucial role in the transformation induced by Η-ras gene in CEF. In 
addition, Fra-1 protein induces morphological transformation and increases invasiveness and 
motility of mouse adenocarcinoma cells [25]. 
3. Models to study Ras signalling to AP-1 
The analysis of multistage carcinogenesis has been facilitated by animal model systems, which 
have formed the basis for much of our present understanding of the genetic and biological 
changes involved in the development of solid tumours. In particular, mouse skin has provided 
the paradigm for studies of multistage carcinogenesis in rodents [26]. Carcinogenesis can be 
initiated in normal epithelial cells by a single treatment of the skin with a variety of chemical 
mutagens, which have previously been shown to induce carcinogen -specific mutations in the 
Η-ras gene [27]. Mutations in the Η-ras gene confer a selective advantage upon initiated cells, 
which then develop into benign tumours after treatment with promoting agents such as 12-0-
tetradecanoyl phorbol-13-acetate (TPA). 
A series of cell lines representing different stages of mouse skin tumour progression has 
been created. These include immortalised non-tumourigenic keratinocyte lines, benign 
papilloma cell lines and squamous carcinoma cell lines, which give rise to well differentiated 
tumours upon injection into nude mice. Highly anaplastic, invasive spindle cell lines which 
have been shown to invade in vitro and exhibit extremely aggressive tumour growth, including 
metastasis in vivo have been established [28-29]. These cell lines are representative for the 
development of three distinct stages in mouse carcinogenesis including benign papillomas, 
locally invasive squamous carcinomas and metastatic spindle carcinomas. All the cell lines have 
been extensively characterised with regard to the status of a number of oncogenes and tumour 
suppressor genes, including Η-ras, p53, cyclin D, Rb and pI6 [29-31; and unpublished results]. 
These cells therefore allow comparison of the specific changes associated with malignant 
progression. 
We have chosen cell lines that all except the control were obtained from tumours 
initiated in vivo with DMBA, and consequently carry the Η-ras mutation at codon 61, which is 
typically induced by this initiating agent [32]. It It has been demonstrated that the mutant H-ras 
gene copy number and expression levels are in line with the level of malignancy of the cell line 
(S. Frame, R. Crombie and A.B., unpublished). The spindle carcinoma cell line carB also shows 
relatively high expression of the mutant ras allele, but in addition has lost the normal allele [33]. 
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Fig. 1. AP-1 in cell signalling. Schematic representation of the regulation of AP-1 components at multiple levels 
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We analysed the expression patterns of Jun, Fos and ATF-2 proteins during mouse skin 
carcinogenesis and we show that phosphorylated forms of c-Jun, Fra-1, Fra-2 and ATF-2 
proteins are expressed in higher amounts in the squamous carcinoma cell lines and especially in 
metastatic cell lines with a spindle morphology. Hyper-phosphorylation of Jun and ATF-2 
correlates with high JNK kinase activity in tumor cells. AP-1 DNA binding and trans-activation 
activity were found elevated in the malignant cell lines, peaking in the fully metastatic cell 
lines. Our results also suggest, for the first time, that ATF-2 plays an important role in the 
progression of mouse skin tumours [34]. 
4. Ras inducible systems 
The importance of Ras mutation has been highlighted by the recent report that primary human 
epithelial and fibroblast cells can be rendered tumourigenic by the ectopic expression of 
telomerase catalytic subunit (hTERT) in combination with the SV40 Τ oncogene and the 
activated (V12G; GTP-bound) mutant allele of Harvey-Ras [35]. 
Whilst experiments utilising over-expression of Ras or its potential downstream 
mediators have yielded a wealth of information over the last decade, one basic criticism is that 
the continued presence of an activated component of cellular signaling renders the study of 
early Ras-mediated signaling impossible. The employment of the scrape-loading technique 
whereby milligram amounts of recombinant Ras protein are added to cell cultures partially 
overcomes this obstacle but the system suffers from the fact that the levels of Ras are not 
physiologically relevant. We therefore selected an ecdysone inducible gene-expression system 
[36] in order to investigate early Ras-mediated signaling events in NIH3T3 mouse fibroblasts. 
Using this system, we are able to rapidly induce expression of activated (V12G) Ha-Ras 
in a dose-dependent manner and at physiological levels equivalent to chemically-induced 
carginogenic epithelial cells derived from BalbC mice. Comparison with NIH3T3 cells over-
expressing Ha-Ras (clone RI, a kind gift from M. Yaniv, Institut Pasteur, France) [37] reveals 
that the peak induction of Ha-Ras is at least 10-fold less than that occurring in the constitutively 
expressing cells. Upon induction of the activated (VI2G) Ha-Ras molecule, NIH3T3 cells 
display transformation-like characteristics such as morphological change, colony formation in 
soft agar, and continued growth in the absence of growth factors . Analysis of cellular signaling 
by Western Blotting reveals a rapid induction of the MAPK pathway (using anti-Phospho 
ERK1/2 antibody) similar to that reported previously. Interestingly the induced ERK signal is 
approximately 5-fold stronger than that found in Rl cells that constitutively over-express Ha-
Ras and hence are continuously signaling through the MAPK cascade, suggesting a de-
sensitisation event has occurred in these cells. Analysis of other signal transduction pathways 
reveals a delayed but transient induction of the SAPK pathway (anti-Phospho JNK antibody). 
No activation of the p38 MAPK pathway has been observed. Activation of both pathways was 
functionally confirmed by kinase assay utilising GST-ELK or GST-c-Jun as the target substrates 
for ERK and JNK respectively. In addition, a corresponding dose-dependent increase in AP-1 
DNA binding activity was observed.. Our results confirm that MAPK is rapidly and 
constitutively activated by the presence of activated Ras, In addition the data suggests that 
SAPK is indirectly activated by Ras and implies that activation of SAPK is tightly regulated due 
to the transient nature of the signal. It is not known whether continuous exposure to Ha-Ras 
signaling will eventual lead to a change in the composition of the AP-1 complex. 
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Fig. 2. Comparative analysis of AP-1 components between tumour cells bearing Ras mutations and cells containing inducible Ras oncogene. 
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5. Concluding remarks 
In conclusion, these data highlight the differences in detected signal transduction when comparing 
early to late exposure to Ras, and suggest that The Ecdysone inducible expression of Ha-Ras is a 
more relevant model in which to investigate potential blockade of Ras-mediated transformation, and 
in addition might lead to the identification of novel targets for therapeutic intervention. 
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